Defining high-risk acute lymphoblastic leukaemia
Dr Ching-Hon Pui speaks to ecancer at the 2020 ALL Assembly meeting in Frankfurt about the definition of high-risk acute lymphoblastic leukaemia (ALL).
He explains that high-risk patients cannot be defined based on their immunophenotype, genotype or measuring their early treatment response using minimal residual disease (MRD).
Dr Pui explains that in order to identify these patients, multiple factors such as presenting clinical features, age and germline features.
He discusses the latest research in this area which explore the heterogeneity of the disease and cooperative mutations.
Dr Pui believes that in the next five years, clinicians will be using most of these factors to determine the risk of the patient and therefore the appropriate treatment strategy.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php
-
Category
No comments found